
Amgen’s Kyprolis has been given another endorsement by the FDA as a multiple myeloma treatment – its second in six …

The FDA has accepted for priority review Amgen’s supplemental new drug application for Kyprolis (carfilzomib) for patients with relapsed multiple …

Results from a Phase III study of a new multiple myeloma offering have found promising results for a treatment that …

